alanyl-glutamyl-aspartyl-glycine has been researched along with Adenocarcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alimova, IN; Anisimov, VN; Francheski, K; Khavinsov, VKh; Manchini, R; Provintsiali, M | 1 |
| Alimova, IN; Anisimov, VN; Khavinson, VKh; Semchenko, AV; Yashin, AI | 1 |
| Alimova, IN; Anisimov, VN; Bashurin, DA; Franceschi, C; Khavincon, BKh; Popovich, IG; Provinciali, M; Volkov, MA; Zabezhinskiĭ, MA | 1 |
3 other study(ies) available for alanyl-glutamyl-aspartyl-glycine and Adenocarcinoma
| Article | Year |
|---|---|
Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Dipeptides; Female; Gene Expression; Genes, erbB-2; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Oligopeptides; Random Allocation; RNA, Messenger | 2002 |
Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.
Topics: Adenocarcinoma; Aging; Animals; Breast Neoplasms; Mice; Mice, Transgenic; Oligopeptides; Receptor, ErbB-2 | 2002 |
[Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Dipeptides; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Oligopeptides | 2002 |